PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

Korábbi kezelés

• Had malignant tumors other than esophageal cancer within 5 years prior to admission (cured localized tumors were not excluded, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ, etc.); Prostate cancer patients who received hormone therapy and obtained DFS for more than 5 years were not excluded).
• Prior history of interstitial lung disease, or pneumonia requiring steroid treatment when enrolled;
• Receiving systemic steroid therapy (more than 10mg of prednisone per day or equivalent) or other immunosuppressant within 2 weeks prior to randomization;

Más betegség

• People who have been severely allergic to chemotherapy drugs (fluorouracil) or any monoclonal antibody;
• Patients with active autoimmune diseases;
• Patients with active hepatitis

Egyéb

• According to the judgment of the researcher, there are other circumstances that are not suitable for participation in this study.

• Age 18-75 years old, gender is not limited;
• Patients with esophageal squamous cell carcinoma with neoadjuvant immunotherapy combined with chemotherapy (radiotherapy was not planned during the study period);
• Thoracic esophageal squamous cell carcinoma patients with residual pathologic primary site and lymph node positive (ypT1-4aN0M0) after surgery (8th UICC-TNM stage);
• The operation was radical resection;
• Physical status ECOG 0 ~ 1 score;
• No local recurrence or distant metastasis was found in the examination before postoperative adjuvant treatment;
• There were no contraindications of chemotherapy or immunotherapy in the evaluation of various organ functions;
• Understand and sign the informed consent.